Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.

Citryll is a biotech company developing therapies for immune-mediated inflammatory diseases, focusing on a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).

Purespring Therapeutics is a gene therapy company specializing in developing treatments for kidney diseases using a proprietary adeno-associated viral (AAV) platform.

LoQus23 Therapeutics develops small molecule drugs to halt DNA instability and slow neurodegeneration in triplet repeat diseases like Huntington's disease.

Novameat develops innovative plant-based food products with a unique fibrous texture using proprietary technology to meet the demand for healthier and sustainable food options.

SOLASTA Bio develops peptide-based, nature-inspired bioinsecticides as sustainable alternatives to synthetic chemicals in the insecticide market.

Navigator Medicines develops biologics for targeted immune regulation and restoration, focusing on OX40L-targeted mono- and bispecific antibodies.

VectorY Therapeutics is a biotech company focused on developing vectorized antibody therapies for neurodegenerative diseases, with a lead program targeting Amyotrophic Lateral Sclerosis (ALS).

Aiolos Bio is a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions, with a lead drug candidate, AIO-001, that is a potentially best-in-class TSLP antibody dosed every 6 months.

Rampart Bioscience is a biotechnology company developing next-generation biologics using their proprietary DNA-based medicines platform, HALO, with a focus on treating hypophosphatasia.

Tessellate BIO is a preclinical stage biotechnology company that develops precision oncology medicines targeting the DNA damage response and cancers relying on Alternative Lengthening of Telomeres (ALT).

Mariana Oncology is a biotechnology company that develops targeted peptide-based radiopharmaceuticals for the treatment of cancer, with a focus on delivering optimized radiation doses to solid tumors.